Literature DB >> 28446576

Diagnostic Value of Galactomannan Antigen Test in Serum and Bronchoalveolar Lavage Fluid Samples from Patients with Nonneutropenic Invasive Pulmonary Aspergillosis.

Wei Zhou1, Hongxing Li2, Yan Zhang1, Mei Huang3, Qian He2, Pei Li1, Fang Zhang1, Yi Shi1, Xin Su4,2.   

Abstract

The objective of this study was to compare the diagnostic value of galactomannan (GM) detection in bronchoalveolar lavage fluid (BALF) and serum samples from nonneutropenic patients with invasive pulmonary aspergillosis (IPA) and determine the optimal BALF GM cutoff value for pulmonary aspergillosis. GM detection in BALF and serum samples was performed by enzyme-linked immunosorbent assay (ELISA) in 128 patients with clinically suspected nonneutropenic pulmonary aspergillosis between June 2014 and June 2016. On the basis of the clinical and pathological diagnoses, 8 patients were excluded because their diagnosis was uncertain. The remaining 120 patients were diagnosed with either IPA (n = 37), community-acquired pneumonia (CAP; n = 59), noninfectious diseases (n = 19), or tuberculosis (n = 5). At a cutoff optical density index (ODI) value of ≥0.5, the sensitivity of BALF GM detection was much higher than that of serum GM detection (75.68% versus 37.84%; P = 0.001), but there was no significant difference between their specificities (80.72% versus 87.14%; P = 0.286). At a cutoff value of ≥1.0, the sensitivity of BALF GM detection was still much higher than that of serum GM detection (64.86% versus 24.32%; P < 0.001), and their specificities were similar (90.36% versus 95.71%; P = 0.202). Receiver operating characteristic (ROC) curve analysis showed that when the BALF GM detection cutoff value was 0.7, its diagnostic value for pulmonary aspergillosis was optimized, and the sensitivity and specificity reached 72.97% and 89.16%, respectively. BALF GM detection was valuable for the diagnosis of IPA in nonneutropenic patients, and its diagnostic value was superior to that of serum GM detection. The optimal BALF GM cutoff value was 0.7.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  bronchoalveolar lavage fluid; galactomannan antigen; invasive pulmonary aspergillosis; nonneutropenic patients

Mesh:

Substances:

Year:  2017        PMID: 28446576      PMCID: PMC5483917          DOI: 10.1128/JCM.00345-17

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination.

Authors:  Jeffrey J Tarrand; Mathias Lichterfeld; Irfan Warraich; Mario Luna; Xiang Y Han; Gregory S May; Dimitrios P Kontoyiannis
Journal:  Am J Clin Pathol       Date:  2003-06       Impact factor: 2.493

2.  Comparison of real-time PCR, conventional PCR, and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive pulmonary aspergillosis.

Authors:  Maurizio Sanguinetti; Brunella Posteraro; Livio Pagano; Gabriella Pagliari; Luana Fianchi; Luca Mele; Marilena La Sorda; Angelica Franco; Giovanni Fadda
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

3.  Serum Aspergillus galactomannan antigen testing by sandwich ELISA: practical use in neutropenic patients.

Authors:  S Bretagne; A Marmorat-Khuong; M Kuentz; J P Latgé; E Bart-Delabesse; C Cordonnier
Journal:  J Infect       Date:  1997-07       Impact factor: 6.072

4.  Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey.

Authors:  A Cornillet; C Camus; S Nimubona; V Gandemer; P Tattevin; C Belleguic; S Chevrier; C Meunier; C Lebert; M Aupée; S Caulet-Maugendre; M Faucheux; B Lelong; E Leray; C Guiguen; J-P Gangneux
Journal:  Clin Infect Dis       Date:  2006-07-27       Impact factor: 9.079

5.  Receptor-mediated clearance of Aspergillus galactomannan.

Authors:  J E Bennett; M M Friedman; B Dupont
Journal:  J Infect Dis       Date:  1987-05       Impact factor: 5.226

6.  Use of bronchoalveolar lavage to detect galactomannan for diagnosis of pulmonary aspergillosis among nonimmunocompromised hosts.

Authors:  M Hong Nguyen; Reia Jaber; Helen L Leather; John R Wingard; Benjamin Staley; L Joseph Wheat; Christina L Cline; Maher Baz; Kenneth H Rand; Cornelius J Clancy
Journal:  J Clin Microbiol       Date:  2007-06-27       Impact factor: 5.948

7.  [Evaluation of risk factors for invasive pulmonary aspergillosis and detection of diagnostic values of galactomannan and PCR methods in bronchoalveolar lavage samples from non-neutropenic intensive care unit patients].

Authors:  Selçuk Özger; Kenan Hızel; Ayşe Kalkancı; Müge Aydoğdu; Füsun Civil; Murat Dizbay; Gül Gürsel
Journal:  Mikrobiyol Bul       Date:  2015-10       Impact factor: 0.622

8.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

9.  The utility of galactomannan antigen in the bronchial washing and serum for diagnosing pulmonary aspergillosis.

Authors:  Yuta Kono; Kenji Tsushima; Koichi Yamaguchi; Nao Kurita; Seiko Soeda; Akahito Fujiwara; Shinya Sugiyama; Yuki Togashi; Satoshi Kasagi; Masako To; Yasuo To; Yasuhiro Setoguchi
Journal:  Respir Med       Date:  2013-04-28       Impact factor: 3.415

10.  Invasive Pulmonary Aspergillosis with Disseminated Infection in Immunocompetent Patient.

Authors:  Gabriel Moreno-González; Antoni Ricart de Mesones; Rachid Tazi-Mezalek; Maria Teresa Marron-Moya; Antoni Rosell; Rafael Mañez
Journal:  Can Respir J       Date:  2016-05-05       Impact factor: 2.409

View more
  47 in total

1.  Utility of Serum and Bronchoalveolar Lavage Fluid Galactomannan in Diagnosis of Chronic Pulmonary Aspergillosis.

Authors:  Inderpaul Singh Sehgal; Sahajal Dhooria; Hansraj Choudhary; Ashutosh Nath Aggarwal; Mandeep Garg; Arunaloke Chakrabarti; Ritesh Agarwal
Journal:  J Clin Microbiol       Date:  2019-02-27       Impact factor: 5.948

2.  Pulmonary Aspergillosis in Patients with Suspected Ventilator-associated Pneumonia in UK ICUs.

Authors:  Laura Loughlin; Thomas P Hellyer; P Lewis White; Danny F McAuley; Andrew Conway Morris; Raquel B Posso; Malcolm D Richardson; David W Denning; A John Simpson; Ronan McMullan
Journal:  Am J Respir Crit Care Med       Date:  2020-10-15       Impact factor: 21.405

3.  A transcriptional signature accurately identifies Aspergillus Infection across healthy and immunosuppressed states.

Authors:  Julie M Steinbrink; Aimee K Zaas; Marisol Betancourt; Jennifer L Modliszewski; David L Corcoran; Micah T McClain
Journal:  Transl Res       Date:  2020-02-20       Impact factor: 7.012

Review 4.  Updates in Laboratory Diagnostics for Invasive Fungal Infections.

Authors:  David Terrero-Salcedo; Margaret V Powers-Fletcher
Journal:  J Clin Microbiol       Date:  2020-05-26       Impact factor: 5.948

Review 5.  Respiratory Mycoses in COPD and Bronchiectasis.

Authors:  Pei Yee Tiew; Micheál Mac Aogáin; Soo Kai Ter; Stefano Aliberti; James D Chalmers; Sanjay H Chotirmall
Journal:  Mycopathologia       Date:  2021-03-11       Impact factor: 2.574

Review 6.  Aspergillus fumigatus and aspergillosis: From basics to clinics.

Authors:  A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl
Journal:  Stud Mycol       Date:  2021-05-10       Impact factor: 16.097

7.  Atti Le giornate della ricerca scientificae delle esperienze professionali dei giovani: Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SItI) Roma 20-21 dicembre 2019.

Authors: 
Journal:  J Prev Med Hyg       Date:  2020-02-13

8.  Diagnostic value of galactomannan test in non-immunocompromised critically ill patients with influenza-associated aspergillosis: data from three consecutive influenza seasons.

Authors:  Linna Huang; Yingfang Zhang; Lin Hua; Qingyuan Zhan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-04-10       Impact factor: 3.267

9.  Update on Non-Culture-Based Diagnostics for Invasive Fungal Disease.

Authors:  Gabriel Yan; Ka Lip Chew; Louis Yi Ann Chai
Journal:  Mycopathologia       Date:  2021-07-02       Impact factor: 2.574

10.  Diagnostic Value of Galactomannan in Bronchoalveolar Lavage Fluid for Chronic Respiratory Disease with Pulmonary Aspergillosis.

Authors:  Guangbin Lai; Chao Zeng; Jianming Mo; Wei-Dong Song; Ping Xu
Journal:  J Clin Microbiol       Date:  2020-02-24       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.